Volume 15 Supplement 1
Atorvastatin for preventing the progression of sepsis to severe sepsis (ASEPSIS Trial): a randomised, double-blind, placebo-controlled trial (ISRCTN64637517)
© Patel et al. 2011
Published: 1 March 2011
Statins have pleiotrophic effects independent of their lipid-lowering properties and may modulate the pathophysiology of sepsis, prevent sepsis progression and improve outcomes . This study evaluated the acute use of Atorvastatin in reducing sepsis progression compared with placebo in statin-naive individuals.
A single-centre, randomised placebo-controlled, double-blind trial (RCT). Ethical approval and consents were obtained. Patients with sepsis, based on the Surviving Sepsis Campaign Guidelines (SSCG), were randomised to Atorvastatin 40 mg daily or placebo for length of hospital stay or 28 days if earlier. Patients on statins were excluded. Primary outcome was progression to severe sepsis, defined by the SSCG.
This is the first RCT to show that the acute use of Atorvastatin can prevent sepsis progression in statin-naive individuals. A multicentred RCT is required to elucidate the mechanisms and clinical applications of these findings.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.